

# Antti Rannikko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4436097/publications.pdf>

Version: 2024-02-01

145  
papers

7,109  
citations

117625

34  
h-index

60623

81  
g-index

153  
all docs

153  
docs citations

153  
times ranked

7997  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up. <i>European Urology Focus</i> , 2022, 8, 1151-1156.	3.1	2
2	Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 465-477.	3.4	9
3	Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and Progression. <i>Cancers</i> , 2022, 14, 532.	3.7	7
4	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199.	2.5	13
5	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.4	13
6	Spectral decoupling for training transferable neural networks in medical imaging. <i>IScience</i> , 2022, 25, 103767.	4.1	2
7	Detecting disease associated biomarkers by luminescence modulating phages. <i>Scientific Reports</i> , 2022, 12, 2433.	3.3	3
8	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. <i>Cancer Research Communications</i> , 2022, 2, 172-181.	1.7	2
9	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. <i>Prostate</i> , 2022, 82, 876-879.	2.3	2
10	AI Model for Prostate Biopsies Predicts Cancer Survival. <i>Diagnostics</i> , 2022, 12, 1031.	2.6	2
11	A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer—Data from the International Multicenter Prospective PRIAS Study. <i>European Urology Oncology</i> , 2022, 5, 651-658.	5.4	13
12	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. <i>BMJ Open</i> , 2022, 12, e050264.	1.9	5
13	Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. <i>European Urology Open Science</i> , 2022, 41, 63-73.	0.4	3
14	Abstract 2234: Incidence of clinically significant prostate cancer after negative prostate MRI - comparison to general population. <i>Cancer Research</i> , 2022, 82, 2234-2234.	0.9	0
15	Abstract 5171: Gene expression in multi-parametric MRI visible and invisible prostate cancers predicts progression. <i>Cancer Research</i> , 2022, 82, 5171-5171.	0.9	0
16	Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression. <i>Oncolmmunology</i> , 2022, 11, .	4.6	20
17	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	2.5	15
18	Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. <i>Human Gene Therapy</i> , 2021, 32, 192-202.	2.7	13

#	ARTICLE	IF	CITATIONS
19	A first step towards a global nomogram to predict disease progression for men on active surveillance. <i>Translational Andrology and Urology</i> , 2021, 10, 1102-1109.	1.4	0
20	Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers. <i>Prostate</i> , 2021, 81, 368-376.	2.3	6
21	What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1048-1054.	3.9	10
22	Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up. <i>European Urology Open Science</i> , 2021, 28, 43-46.	0.4	2
23	Urinary extracellular vesicles: Assessment of pre-analytical variables and development of a quality control with focus on transcriptomic biomarker research. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12158.	12.2	26
24	PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification. <i>ACS Nano</i> , 2021, 15, 15992-16010.	14.6	17
25	Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non-protocol-based Follow-up and a Protocol-based Contemporary Follow-up. <i>European Urology Open Science</i> , 2021, 34, 33-40.	0.4	1
26	Prostate Cancer-specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users. <i>European Urology Open Science</i> , 2021, 34, 86-93.	0.4	3
27	Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking. <i>Journal of Robotic Surgery</i> , 2020, 14, 271-274.	1.8	1
28	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
29	Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. <i>International Journal of Cancer</i> , 2020, 146, 1175-1175.	5.1	0
30	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1556-1567.	3.4	22
31	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. <i>Cancer Imaging</i> , 2020, 20, 72.	2.8	10
32	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. <i>Oncolmmunology</i> , 2020, 9, 1761229.	4.6	22
33	PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. <i>Prostate</i> , 2020, 80, 1118-1127.	2.3	2
34	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. <i>PLoS ONE</i> , 2020, 15, e0235779.	2.5	8
35	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 7, 1316-1323.	3.1	4
36	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 32-32.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0235779.		0
38	Title is missing!. , 2020, 15, e0235779.		0
39	Title is missing!. , 2020, 15, e0235779.		0
40	Title is missing!. , 2020, 15, e0235779.		0
41	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patient-derived cancer cells. International Journal of Cancer, 2019, 144, 1356-1366.	5.1	29
42	Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland—a nationwide cohort study. International Journal of Cancer, 2019, 144, 440-447.	5.1	22
43	Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 424-430.	1.2	1
44	Improving Prostate Cancer Detection with Breast Histopathology Images. Lecture Notes in Computer Science, 2019, , 91-99.	1.3	8
45	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. Prostate, 2019, 79, 1505-1513.	2.3	23
46	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	1.9	18
47	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine, 2019, 16, e1002813.	8.4	43
48	PCASTt/SPCG-17—a randomised trial of active surveillance in prostate cancer: rationale and design. BMJ Open, 2019, 9, e027860.	1.9	19
49	Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1642-1651.	2.5	13
50	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
51	Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate, 2019, 79, 583-591.	2.3	21
52	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
53	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. European Urology Focus, 2019, 5, 443-448.	3.1	16
54	Abstract 1396: Detection and local histological staging of prostate cancer foci in H&E whole slide images using convolutional neural networks. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
55	Abstract 3486: Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer. , 2019, , .		0
56	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from <i>Kras</i>-driven lung tumours. Journal of Pathology, 2018, 245, 101-113.	4.5	19
57	Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1055-1060.	2.9	6
58	Antibiotic susceptibility of intestinal <i>Escherichia coli</i> in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU International, 2018, 122, 203-210.	2.5	14
59	New prostate cancer grade grouping system predicts survival after radical prostatectomy. Human Pathology, 2018, 75, 159-166.	2.0	17
60	ITGB1-dependent upregulation of Caveolin-1 switches TGF $\beta$ 2 signalling from tumour-suppressive to oncogenic in prostate cancer. Scientific Reports, 2018, 8, 2338.	3.3	29
61	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	27.0	2,036
62	PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. European Urology Focus, 2018, 4, 867-873.	3.1	30
63	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scandinavian Journal of Urology, 2018, 52, 313-320.	1.0	40
64	Patient Experience of Systematic Versus Fusion Prostate Biopsies. European Urology Oncology, 2018, 1, 202-207.	5.4	20
65	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology, 2018, 1, 268-275.	5.4	5
66	Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. Oncotarget, 2018, 9, 31200-31213.	1.8	19
67	Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Translational Andrology and Urology, 2018, 7, 98-105.	1.4	24
68	Triggers for Intervention. Current Clinical Urology, 2018, , 83-94.	0.0	0
69	Abstract 4602: PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. , 2018, , .		0
70	Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine. , 2018, , .		0
71	Editorial Comment. Journal of Urology, 2018, 200, 1034-1034.	0.4	1
72	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. European Urology, 2017, 71, 319-327.	1.9	74

#	ARTICLE	IF	CITATIONS
73	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	1.9	190
74	Semantics in active surveillance for men with localized prostate cancer — results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017, 14, 312-322.	3.8	65
75	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. <i>European Journal of Epidemiology</i> , 2017, 32, 521-527.	5.7	36
76	KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 98, 30-39.	4.0	59
77	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	1.9	11
78	Precision systems medicine in urological Tumors — Molecular profiling and functional testing. <i>Annals of Oncology</i> , 2017, 28, vii2.	1.2	0
79	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. <i>Theranostics</i> , 2017, 7, 3824-3841.	10.0	167
80	Repeat multiparametric MRI in prostate cancer patients on active surveillance. <i>PLoS ONE</i> , 2017, 12, e0189272.	2.5	23
81	Abstract 5732: PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer. , 2017, , .		1
82	Abstract 3854: Precision medicine approach: analysis of renal cancer patient-derived cells with phenomics, genomics and drug sensitivity profiling. , 2017, , .		0
83	Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care. <i>Scandinavian Journal of Urology</i> , 2016, 50, 149-154.	1.0	16
84	Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. <i>Scandinavian Journal of Urology</i> , 2016, 50, 330-337.	1.0	15
85	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. <i>Modern Pathology</i> , 2016, 29, 1565-1574.	5.5	43
86	Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005—2013: a population-based analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 417-422.	3.9	14
87	A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. <i>European Urology</i> , 2016, 70, 954-960.	1.9	290
88	Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study. <i>BJU International</i> , 2016, 118, 366-371.	2.5	51
89	Active surveillance for prostate cancer: a narrative review of clinical guidelines. <i>Nature Reviews Urology</i> , 2016, 13, 151-167.	3.8	139
90	Abstract 608: Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. , 2016, , .		1

#	ARTICLE	IF	CITATIONS
91	PD34-04 FREQUENCY OF PSA TESTING IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER.. Journal of Urology, 2015, 193, .	0.4	3
92	Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. European Urology, 2015, 67, 627-636.	1.9	284
93	Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. European Urology, 2015, 68, 814-821.	1.9	116
94	Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy. Scandinavian Journal of Urology, 2015, 49, 90-96.	1.0	6
95	Effects of resistance training on testosterone metabolism in younger and older men. Experimental Gerontology, 2015, 69, 148-158.	2.8	20
96	Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World Journal of Urology, 2015, 33, 1735-1740.	2.2	7
97	Androgen receptor-interacting protein <sc>HSPBAP1</sc> facilitates growth of prostate cancer cells in androgen-deficient conditions. International Journal of Cancer, 2015, 136, 2535-2545.	5.1	10
98	Abstract 207: Caveolin-1 drives oncogenic TGF $\beta$ 2 effects in prostate cancer: in vitro mechanistic insights integrated with systems pathology visualization in primary tumor samples. , 2015, , .		0
99	Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: Retrospective analysis of safety profile and effect on blood coagulation. Scandinavian Journal of Urology, 2014, 48, 153-159.	1.0	10
100	MP62-10 OUTCOME IN MEN CONTINUING ACTIVE SURVEILLANCE DESPITE PROTOCOL ADVICE TO DISCONTINUE. Journal of Urology, 2014, 191, .	0.4	0
101	684: Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers. European Journal of Cancer, 2014, 50, S164.	2.8	0
102	273: Androgen receptor interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. European Journal of Cancer, 2014, 50, S64.	2.8	0
103	Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. European Urology, 2013, 63, 597-603.	1.9	450
104	1353 CHANGE IN CANCER LOCATION AND ACCUMULATION OF CANCER LOCI AND LENGTH PREDICT TREATMENT CHANGE IN PROSPECTIVE ACTIVE SURVEILLANCE COHORT. RESULTS OF THE FINNISH ARM OF THE PRIAS TRIAL. Journal of Urology, 2013, 189, .	0.4	0
105	Active surveillance for low-risk prostate cancer. Critical Reviews in Oncology/Hematology, 2013, 85, 295-302.	4.4	46
106	Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy. Scandinavian Journal of Urology, 2013, 47, 456-461.	1.0	20
107	Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncol $\beta$ gica, 2013, 52, 1615-1621.	1.8	20
108	Editorial Comment to: SAMS: A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scandinavian Journal of Urology, 2013, 47, 356-356.	1.0	1

#	ARTICLE	IF	CITATIONS
109	Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. <i>BJU International</i> , 2012, 110, 1672-1677.	2.5	125
110	Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. <i>Oncogene</i> , 2012, 31, 3444-3456.	5.9	112
111	Predictors of Unfavourable Repeat Biopsy Results in Men Participating in a Prospective Active Surveillance Program. <i>European Urology</i> , 2012, 61, 370-377.	1.9	64
112	Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. <i>European Urology</i> , 2012, 62, 195-200.	1.9	89
113	Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. <i>BJU International</i> , 2012, 109, 1614-1619.	2.5	56
114	Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. <i>EMBO Journal</i> , 2011, 30, 3962-3976.	7.8	318
115	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. <i>Oncotarget</i> , 2011, 2, 1176-1190.	1.8	77
116	Abstract 2597: PLA2G7 associates with aggressive prostate cancer in vivo and regulates prostate cancer cell migration and adhesion in vitro. , 2011, , .		0
117	Short-term outcomes of the prospective multicentre Prostate Cancer Research International: Active Surveillance™ study. <i>BJU International</i> , 2010, 105, 956-962.	2.5	157
118	Robotics in Surgery. <i>Scandinavian Journal of Surgery</i> , 2009, 98, 71-71.	2.6	1
119	Outcomes of Men with Screen-Detected Prostate Cancer Eligible for Active Surveillance Who Were Managed Expectantly. <i>European Urology</i> , 2009, 55, 1-8.	1.9	242
120	Re: Active Surveillance for the Management of Prostate Cancer in a Contemporary Cohort. <i>European Urology</i> , 2009, 55, 244-245.	1.9	1
121	Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. <i>BJU International</i> , 2009, 103, 1472-1477.	2.5	42
122	Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestrogen supplementation. <i>Prostate</i> , 2006, 66, 82-87.	2.3	51
123	The effects of short-term oral phytoestrogen supplementation on the hypothalamic-pituitary-testicular axis in prostate cancer patients. <i>Prostate</i> , 2006, 66, 1086-1091.	2.3	19
124	Rapid progression of small cell carcinoma in a renal transplant recipient. <i>International Journal of Urology</i> , 2006, 13, 817-819.	1.0	3
125	Incidence and Follow-Up of Patients with Focal Prostate Carcinoma in 2 Screening Rounds After an Interval of 4 Years. <i>European Urology</i> , 2006, 49, 411.	1.9	0
126	Quantification of prostate specific antigen mRNA levels in circulation after prostatic surgery and endocrine treatment by quantitative reverse transcription-polymerase chain reaction. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2004, 64, 93-100.	1.2	13

#	ARTICLE	IF	CITATIONS
127	Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. <i>Urology</i> , 2004, 64, 955-958.	1.0	82
128	Cavoatrial Extension of Renal Cell Cancer: Results of Operative Treatment in Helsinki University Hospital between 1990 and 2000. <i>Scandinavian Journal of Surgery</i> , 2004, 93, 213-216.	2.6	8
129	Down-Regulation of Estrogen Receptor $\hat{2}$ and Transcriptional Coregulator SNURF/RNF4 in Testicular Germ Cell Cancer. <i>European Urology</i> , 2003, 44, 742-747.	1.9	27
130	Functional characterization of the human FSH receptor with an inactivating Ala189Val mutation. <i>Molecular Human Reproduction</i> , 2002, 8, 311-317.	2.8	79
131	Experimental cryptorchidism induces a change in the pattern of expression of LH receptor mRNA in rat testis after selective Leydig cell destruction by ethylene dimethane sulfonate. <i>Journal of Endocrinology</i> , 1999, 161, 131-141.	2.6	9
132	The Pattern of Inhibin/Activin $\hat{A}$ - and $\hat{B}$ -Subunit Messenger Ribonucleic Acid Expression in Rat Testis after Selective Leydig Cell Destruction by Ethylene Dimethane Sulfonate. <i>Endocrinology</i> , 1999, 140, 5761-5770.	2.8	8
133	Stable transfection of the rat follicle-stimulating hormone receptor complementary DNA into an immortalized murine Sertoli cell line. <i>Molecular and Cellular Endocrinology</i> , 1998, 139, 143-152.	3.2	18
134	Mechanisms of desensitization of follicle-stimulating hormone (FSH) action in a murine granulosa cell line stably transfected with the human FSH receptor complementary deoxyribonucleic acid. <i>Molecular and Cellular Endocrinology</i> , 1998, 146, 163-176.	3.2	14
135	Gonadotropin-Independent Regulation of Steroidogenesis in the Fetal Rat Testis1. <i>Biology of Reproduction</i> , 1998, 58, 116-123.	2.7	130
136	Recombinant forms of rat and human luteinizing hormone and follicle-stimulating hormone; comparison of functions in vitro and in vivo. <i>Journal of Endocrinology</i> , 1998, 158, 441-448.	2.6	22
137	Molecular Mechanisms of Reappearance of Luteinizing Hormone Receptor Expression and Function in Rat Testis after Selective Leydig Cell Destruction by Ethylene Dimethane Sulfonate <sup>1</sup> . <i>Endocrinology</i> , 1997, 138, 3340-3348.	2.8	34
138	Cloning and Functional Expression of the Luteinizing Hormone Receptor Complementary Deoxyribonucleic Acid from the Marmoset Monkey Testis: Absence of Sequences Encoding Exon 10 in Other Species*. <i>Endocrinology</i> , 1997, 138, 2481-2490.	2.8	65
139	Cloning and Functional Expression of the Luteinizing Hormone Receptor Complementary Deoxyribonucleic Acid from the Marmoset Monkey Testis: Absence of Sequences Encoding Exon 10 in Other Species. <i>Endocrinology</i> , 1997, 138, 2481-2490.	2.8	20
140	Molecular Mechanisms of Reappearance of Luteinizing Hormone Receptor Expression and Function in Rat Testis after Selective Leydig Cell Destruction by Ethylene Dimethane Sulfonate. <i>Endocrinology</i> , 1997, 138, 3340-3348.	2.8	3
141	Ontogeny of endocrine interactions of the rat hypothalamic-pituitary-gonadal axis. <i>Seminars in Cell and Developmental Biology</i> , 1996, 7, 211-218.	5.0	3
142	Stage-specific expression of the FSH receptor gene in the prepubertal and adult rat seminiferous epithelium. <i>Journal of Endocrinology</i> , 1996, 151, 29-35.	2.6	42
143	Developmental expression of the prolactin receptor gene in rat gonads. <i>Journal of Endocrinology</i> , 1995, 147, 497-505.	2.6	15
144	Ontogeny of follicle-stimulating hormone receptor gene expression in the rat testis and ovary. <i>Molecular and Cellular Endocrinology</i> , 1995, 107, 199-208.	3.2	130

#	ARTICLE	IF	CITATIONS
145	Ontogeny of the inhibitory guanine nucleotide-binding regulatory protein in the rat testis: mRNA expression and modulation of LH and FSH action. <i>Molecular and Cellular Endocrinology</i> , 1994, 102, 63-68.	3.2	18